title: Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
abstract: OBJECTIVE
  Glioblastoma is one of the most frequent primitive brain tumors. Patients who experience tumor relapse after surgery and concomitant radiochemotherapy have a dismal prognosis. The objective of this study is to analyze efficacy data in terms of overall survival (OS) and progression- free survival (PFS) following combination therapy with bevacizumab (BVZ) and irinotecan among patients with relapsed glioblastoma. Safety data will also be reviewed and all results will be compared with data of the literature.
  
  
  METHODS
  In this single-center retrospective study, all records of patients treated with BVZ and irinotecan for a relapsed glioblastoma were analyzed. Each chemotherapy cycle was repeated every 15 days until progression. Magnetic resonance imaging and neurologic examination were repeated every 6 weeks during treatment.
  
  
  RESULTS
  Forty-five patients were analyzed. The median number of BVZ-irinotecan cycles was 8 (range 1-38). Median PFS was 26 weeks and median OS was 28 weeks. Eighteen of the 45 patients (40% of cases) had an objective response 6 months after initiation of treatment. Two patients had to discontinue treatment due to toxicity.
  
  
  CONCLUSIONS
  The results of the SV1 study are consistent with those found in phase II studies evaluating the same treatment. The irinotecan-BVZ combination is effective in relapsed glioblastoma with acceptable toxicity. Biomarkers predictive of response to BVZ should help in the selection of patients who could benefit from treatment.
authors.forename: Romain
authors.initials: R
authors.lastname: Rivoirard
authors.forename: Cyrus
authors.initials: C
authors.lastname: Chargari
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Guy
authors.forename: Christophe
authors.initials: C
authors.lastname: Nuti
authors.forename: Michel
authors.initials: M
authors.lastname: Peoc'h
authors.forename: Fabien
authors.initials: F
authors.lastname: Forest
authors.forename: Alexander Tuan
authors.initials: AT
authors.lastname: Falk
authors.forename: Clemence
authors.initials: C
authors.lastname: Garin
authors.forename: Anissa
authors.initials: A
authors.lastname: Adjabi
authors.forename: Delphine
authors.initials: D
authors.lastname: Hoarau
authors.forename: Marie-Jeannette
authors.initials: MJ
authors.lastname: Fotso
authors.forename: Julien
authors.initials: J
authors.lastname: Langrand Escure
authors.forename: Guillaume
authors.initials: G
authors.lastname: Moriceau
authors.forename: Pierre
authors.initials: P
authors.lastname: Fournel
authors.forename: Claire
authors.initials: C
authors.lastname: Boutet
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000000981:diagnostic imaging; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab